Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Sigilon Therapeutics (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 9:30 a.m. EDT. The company focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform. Sigilon's non-viral engineered cell-based therapies target conditions like hemophilia and diabetes, employing Afibromer™ biomaterials to protect cells from immune rejection.

News Market Reaction – SGTX

-2.38%

-2.38% Session move

In the trading session that priced this news, SGTX declined 2.38%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 20^th Annual Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 15 at 9:30 a.m. EDT, in a virtual format.

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contacts
Glenn Reicin
Sigilon Therapeutics, Chief Financial Officer
glenn.reicin@sigilon.com
646-696-4344

Jennifer Porcelli
Solebury Trout
jporcelli@soleburytrout.com
646-378-2962

Media Contact
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

 

FAQ

When is the Sigilon Therapeutics presentation at the Needham Virtual Healthcare Conference?

The presentation is scheduled for April 15, 2021, at 9:30 a.m. EDT.

What is the focus of Sigilon Therapeutics?

Sigilon Therapeutics is focused on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform.

What are Sigilon's engineered cell-based therapies designed to treat?

They are designed to treat chronic diseases such as hemophilia, lysosomal disorders, and diabetes.

What protects Sigilon's engineered cells from rejection?

The cells are protected by Afibromer™ biomaterials, which shield them from immune rejection and fibrosis.

Who will present Sigilon Therapeutics' corporate overview?

Rogerio Vivaldi, M.D., the President and CEO of Sigilon Therapeutics, will present the overview.